May 2025
1. SARRAJU A, Brennan D, Hayden K, Stronczek A, et al
   Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.
   Lancet. 2025;405:1757-1768.
   

   >> Share

   
   December 2023
2. 
   Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study.
   Lancet. 2023 Dec 12:S0140-6736(23)01842-1. doi: 10.1016/S0140-6736(23)01842.
   

   >> Share

   
   
3. MCGOWAN MP, Cuchel M
   Universal paediatric screening for familial hypercholesterolaemia.
   Lancet. 2023 Dec 12:S0140-6736(23)02182-7. doi: 10.1016/S0140-6736(23)02182.
   

   >> Share

   
   November 2023
4. AYOUB A, Akyea RK, L'Esperance V, Ayis S, et al
   Determinants of lipid clinic referral and attendance in a multi-ethnic adult population in south London: a cross-sectional study.
   Lancet. 2023;402 Suppl 1:S26.
   

   >> Share

   
   September 2023
5. MANSFIELD BS, Raal FJ
   Regression of cutaneous xanthomata in patient with homozygous familial hypercholesterolemia using novel therapies.
   Lancet. 2023;402:e11.
   

   >> Share

   
   March 2023
6. RIDKER PM, Bhatt DL, Pradhan AD, Glynn RJ, et al
   Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
   Lancet. 2023 Mar 3:S0140-6736(23)00215-5. doi: 10.1016/S0140-6736(23)00215.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share